An ELISA-based methodology was developed to enable the CDH5 protein levels to be measured in the serum of breast cancer patients alongside assessment of CDH5 glycosylation status using HPA as the glycan recognition molecule (Fry et al, 2013). The gene discussed is CDH5; the disease is breast cancer.